Brokerages expect Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) to announce earnings of ($0.69) per share for the current fiscal quarter, Zacks Investment Research reports. Five analysts have issued estimates for Aerie Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.65) and the lowest estimate coming in at ($0.78). Aerie Pharmaceuticals reported earnings of ($0.84) per share in the same quarter last year, which would indicate a positive year over year growth rate of 17.9%. The business is scheduled to issue its next quarterly earnings report on Wednesday, May 5th.
On average, analysts expect that Aerie Pharmaceuticals will report full-year earnings of ($2.38) per share for the current fiscal year, with EPS estimates ranging from ($2.82) to ($2.16). For the next year, analysts anticipate that the business will report earnings of ($1.32) per share, with EPS estimates ranging from ($2.06) to ($0.75). Zacks’ earnings per share calculations are an average based on a survey of sell-side research analysts that follow Aerie Pharmaceuticals.
Aerie Pharmaceuticals (NASDAQ:AERI) last released its quarterly earnings results on Thursday, February 25th. The company reported ($0.79) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.04). Aerie Pharmaceuticals had a negative net margin of 231.05% and a negative return on equity of 135.57%. The business had revenue of $24.68 million during the quarter, compared to analyst estimates of $21.75 million.
AERI has been the topic of a number of research analyst reports. Needham & Company LLC initiated coverage on shares of Aerie Pharmaceuticals in a research report on Friday, February 5th. They set a “buy” rating and a $26.00 price target on the stock. Mizuho reaffirmed a “buy” rating and issued a $28.00 price objective on shares of Aerie Pharmaceuticals in a report on Monday, December 28th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Aerie Pharmaceuticals in a report on Monday, March 1st. One research analyst has rated the stock with a sell rating, two have given a hold rating and eight have issued a buy rating to the company. Aerie Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $22.70.
Shares of NASDAQ AERI traded up $0.08 during midday trading on Thursday, reaching $17.78. 318,590 shares of the company were exchanged, compared to its average volume of 669,167. The stock’s 50-day moving average price is $18.76 and its 200-day moving average price is $14.96. The stock has a market cap of $834.18 million, a P/E ratio of -4.22 and a beta of 0.79. Aerie Pharmaceuticals has a one year low of $9.01 and a one year high of $21.30. The company has a quick ratio of 3.10, a current ratio of 3.33 and a debt-to-equity ratio of 3.41.
A number of institutional investors have recently made changes to their positions in AERI. JPMorgan Chase & Co. grew its holdings in Aerie Pharmaceuticals by 10.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 13,676 shares of the company’s stock worth $156,000 after acquiring an additional 1,248 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of Aerie Pharmaceuticals by 5.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 282,089 shares of the company’s stock valued at $3,321,000 after purchasing an additional 15,706 shares in the last quarter. Truist Financial Corp bought a new stake in shares of Aerie Pharmaceuticals during the 3rd quarter valued at about $129,000. Squarepoint Ops LLC boosted its stake in shares of Aerie Pharmaceuticals by 86.8% during the 3rd quarter. Squarepoint Ops LLC now owns 35,157 shares of the company’s stock valued at $414,000 after purchasing an additional 16,340 shares in the last quarter. Finally, Voloridge Investment Management LLC boosted its stake in shares of Aerie Pharmaceuticals by 103.4% during the 3rd quarter. Voloridge Investment Management LLC now owns 205,170 shares of the company’s stock valued at $2,415,000 after purchasing an additional 104,282 shares in the last quarter. 99.89% of the stock is currently owned by institutional investors and hedge funds.
About Aerie Pharmaceuticals
Aerie Pharmaceuticals, Inc, an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, ocular surface, and retinal diseases in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma.
Featured Story: The risks of owning bonds
For more information about research offerings from Zacks Investment Research, visit Zacks.com